4d Molecular Therapeutics Share Price (NASDAQ: FDMT)

$6.16

▲

-0.02

(-0.32%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive 4d Molecular Therapeutics Stock chart to analyse performance

4d Molecular Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$6.08
Today's High:$6.24
$6.16
1.3%
Downside
Day's Volatility :2.56%
Upside
1.28%
52 Weeks Low:$2.24
52 Weeks High:$17.41
$6.16
63.72%
Downside
52 Weeks Volatility :87.16%
Upside
64.62%

4d Molecular Therapeutics Stock Returns

Period	4d Molecular Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	63.73%	3.6%	0.0%
6 Months	48.31%	-7.7%	0.0%
1 Year	-58.34%	-12.6%	0.0%
3 Years	-23.63%	9.5%	-4.7%

4d Molecular Therapeutics Inc Key Stats

Check 4d Molecular Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$6.18
Open	$6.24
Today's High	$6.24
Today's Low	$6.08
Market Capitalization	$301.7M
Today's Volume	$342.6K
52 Week High	$17.41
52 Week Low	$2.235
Revenue TTM	$33.0K
EBITDA	$-215.8M
Earnings Per Share (EPS)	$-3.53
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-38.87%

Stock Returns calculator for 4d Molecular Therapeutics Stock including INR - Dollar returns

The 4d Molecular Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

4d Molecular Therapeutics investment value today

Current value as on today

₹47,075

Returns

₹52,925

(-52.92%)

Returns from 4d Molecular Therapeutics Stock

₹58,209 (-58.21%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards 4d Molecular Therapeutics Stock

1733.33%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Investment in 4d Molecular Therapeutics Shares from India has grown by 1733.33% over the past 30 days, indicating increased transactional activity.

500%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for 4d Molecular Therapeutics Stock from India on INDmoney has increased by 500% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in 4d Molecular Therapeutics Inc

Name
Holdings %
Name
Holdings %
Bvf Inc
9.91%
RA Capital Management, LLC
9.77%
BlackRock Inc
9.74%
Goldman Sachs Group Inc
8.91%
Vanguard Group Inc
5.86%
Novo A/S
4.28%

Analyst Recommendation on 4d Molecular Therapeutics Stock

Rating

Trend

Buy

94%Buy

5%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for 4d Molecular Therapeutics(by analysts ranked 0 to 5 stars)

4d Molecular Therapeutics Share Price Target

What analysts predicted

Upside of 393.51%

Target:

$30.40

Current:

$6.16

4d Molecular Therapeutics share price target is $30.40, a slight Upside of 393.51% compared to current price of $6.16 as per analysts' prediction.

4d Molecular Therapeutics Stock Insights

Price Movement
In the last 7 days, FDMT stock has moved down by -13.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 1.0K → 15.0K (in $), with an average increase of 49.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -47.97M → -54.65M (in $), with an average decrease of 13.9% per quarter
FDMT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 129.0%
FDMT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 138.2%
Price to Sales
ForFDMT every $1 of sales, investors are willing to pay $6140.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

4d Molecular Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$7.0M	↓ 50.56%
Net Income	$-52.9M	↑ 454.28%
Net Profit Margin	-757.79%	↓ 690.2%

	FY20	Y/Y Change
Revenue	$13.6M	↑ 94.85%
Net Income	$-56.5M	↑ 6.8%
Net Profit Margin	-415.38%	↑ 342.41%

	FY21	Y/Y Change
Revenue	$18.0M	↑ 32.52%
Net Income	$-68.3M	↑ 20.79%
Net Profit Margin	-378.63%	↑ 36.75%

	FY22	Y/Y Change
Revenue	$3.1M	↓ 82.65%
Net Income	$-101.1M	↑ 47.99%
Net Profit Margin	-3.2K%	↓ 2851.67%

	FY23	Y/Y Change
Revenue	$20.7M	↑ 562.29%
Net Income	$-100.8M	↓ 0.24%
Net Profit Margin	-486.59%	↑ 2743.71%

	FY24	Y/Y Change
Revenue	$37.0K	↓ 99.82%
Net Income	$-160.9M	↑ 59.53%
Net Profit Margin	-434.8K%	↓ 434291.79%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$28.0K	↓ 247.37%
Net Income	$-32.4M	↑ 0.37%
Net Profit Margin	-115.7K%	↓ 285628.39%

	Q2 FY24	Q/Q Change
Revenue	$5.0K	↓ 82.14%
Net Income	$-35.0M	↑ 7.88%
Net Profit Margin	-699.1K%	↓ 583342.14%

	Q3 FY24	Q/Q Change
Revenue	$3.0K	↓ 40.0%
Net Income	$-43.8M	↑ 25.43%
Net Profit Margin	-1.5M%	↓ 762373.33%

	Q4 FY24	Q/Q Change
Revenue	$1000.0	↓ 66.67%
Net Income	$-49.7M	↑ 13.29%
Net Profit Margin	-5.0M%	↓ 3505666.67%

	Q1 FY25	Q/Q Change
Revenue	$14.0K	↑ 1300.0%
Net Income	$-48.0M	↓ 3.42%
Net Profit Margin	-342.7K%	↑ 4624442.86%

	Q2 FY25	Q/Q Change
Revenue	$15.0K	↑ 7.14%
Net Income	$-54.7M	↑ 13.94%
Net Profit Margin	-364.4K%	↓ 21729.53%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-31.7M	↑ 649.81%

	FY20	Y/Y Change
Profit	$-39.4M	↑ 24.25%

	FY21	Y/Y Change
Profit	$18.0M	↓ 145.75%

	FY22	Y/Y Change
Profit	$3.1M	↓ 82.65%

	FY23	Y/Y Change
Profit	$-76.4M	↓ 2540.81%

	FY24	Y/Y Change
Profit	$37.0K	↓ 100.05%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-1.6M	↓ 63.2%

	Q2 FY24	Q/Q Change
Profit	$-1.6M	↑ 3.38%

	Q3 FY24	Q/Q Change
Profit	$3.0K	↓ 100.19%

	Q4 FY24	Q/Q Change
Profit	$-1.8M	↓ 59533.33%

	Q1 FY25	Q/Q Change
Profit	$14.0K	↓ 100.79%

	Q2 FY25	Q/Q Change
Profit	$-1.9M	↓ 13478.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-36.7M	↑ 125.89%
Investing Cash Flow	$-3.2M	↑ 673.67%
Financing Cash Flow	$-2.2M	↓ 102.6%

	FY20	Y/Y Change
Operating Cash Flow	$-50.9M	↑ 38.68%
Investing Cash Flow	$-1000.0K	↓ 68.78%
Financing Cash Flow	$279.0M	↓ 12809.93%

	FY21	Y/Y Change
Operating Cash Flow	$-69.1M	↑ 35.8%
Investing Cash Flow	$-172.7M	↑ 17168.0%
Financing Cash Flow	$118.1M	↓ 57.67%

	FY22	Y/Y Change
Operating Cash Flow	$-86.7M	↑ 25.39%
Investing Cash Flow	$-17.1M	↓ 90.13%
Financing Cash Flow	$3.1M	↓ 97.39%

	FY23	Y/Y Change
Operating Cash Flow	$-75.8M	↓ 12.57%
Investing Cash Flow	$115.7M	↓ 778.69%
Financing Cash Flow	$156.8M	↑ 4983.7%

	FY24	Y/Y Change
Operating Cash Flow	$-134.6M	↑ 77.57%
Investing Cash Flow	$-302.4M	↓ 361.36%
Financing Cash Flow	$337.3M	↑ 115.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-29.1M	↑ 18.0%
Investing Cash Flow	$-263.3M	↑ 3839.81%
Financing Cash Flow	$318.8M	↑ 6595.34%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-30.2M	↑ 3.97%
Investing Cash Flow	$-73.5M	↓ 72.07%
Financing Cash Flow	$17.2M	↓ 94.59%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-29.4M	↓ 2.82%
Investing Cash Flow	$27.3M	↓ 137.12%
Financing Cash Flow	$568.0K	↓ 96.71%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-45.9M	↑ 56.04%
Investing Cash Flow	$7.1M	↓ 74.14%
Financing Cash Flow	$601.0K	↑ 5.81%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-47.8M	↑ 4.13%
Investing Cash Flow	$31.9M	↑ 352.59%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-43.4M	↓ 9.17%
Investing Cash Flow	$-13.9M	↓ 143.36%
Financing Cash Flow	$862.0K	-

4d Molecular Therapeutics Technicals Summary

Sell

Neutral

Buy

4d Molecular Therapeutics is currently in a neutral trading position according to technical analysis indicators.

4d Molecular Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
4d Molecular Therapeutics Inc	36.44%	48.31%	-58.34%	-23.63%	-84.84%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
4d Molecular Therapeutics Inc	NA	NA	NA	-3.69	-0.39	-0.25	NA	9.01
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
4d Molecular Therapeutics Inc	Buy	$301.7M	-84.84%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About 4d Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

Organization	4d Molecular Therapeutics
Employees	227
CEO	Dr. David H. Kirn M.D.
Industry	Healthcare

Key Management of 4d Molecular Therapeutics Inc

Name	Title
Dr. John F. Milligan Ph.D.	Executive Chairman
Dr. David H. Kirn M.D.	Co-Founder, CEO & Director
Dr. Fariborz Kamal Ph.D.	President & COO
Ms. Theresa Janke	Co-Founder & Chief of Staff
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary
Dr. Robert Y. Kim M.B.A., M.D.	Chief Medical Officer
Dr. An Song Ph.D.	Chief Translational Medicine Advisor
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology
Mr. Christopher Paul Simms	Chief Commercial Officer
Ms. Karen S. Carothers	Controller

Important FAQs about investing in FDMT Stock from India :

What is 4d Molecular Therapeutics share price today?

4d Molecular Therapeutics share price today is $6.16 as on August 30, 2025 at 1:29 am IST at the close of the market. 4d Molecular Therapeutics share today touched a day high of $6.24 and a low of $6.08.

What is the 52 week high and 52 week low for 4d Molecular Therapeutics share?

4d Molecular Therapeutics share touched a 52 week high of $17.41 and a 52 week low of $2.24. 4d Molecular Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $6.16, lower by 64.62% versus the 52 week high.

How to invest in 4d Molecular Therapeutics Stock (FDMT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for 4d Molecular Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 4d Molecular Therapeutics Shares that will get you 0.2435 shares as per 4d Molecular Therapeutics share price of $6.16 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy 4d Molecular Therapeutics Stock (FDMT) from India?

Indian investors can start investing in 4d Molecular Therapeutics (FDMT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in 4d Molecular Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on 4d Molecular Therapeutics share’s latest price of $6.16 as on August 30, 2025 at 1:29 am IST, you will get 1.6234 shares of 4d Molecular Therapeutics. Learn more about fractional shares .

What are the returns that 4d Molecular Therapeutics has given to Indian investors in the last 5 years?

4d Molecular Therapeutics stock has given -84.84% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?